Menu

ISTOCK, KKOLOSOV

Effort to Reproduce Cancer Studies Scales Down to 18 Papers

The Reproducibility Project: Cancer Biology initially aimed to replicate the results of 50 high-impact research articles.

Aug 1, 2018
Diana Kwon

A large effort to reproduce high-impact cancer research has scaled down the number of studies it plans to replicate from 50 to 18, Science reported yesterday (July 31). 

The Reproducibility Project: Cancer Biology (RP:CP) was launched by the Center for Open Science and Science Exchange, a biotechnology company, in 2013. The project’s initial aim was to replicate experiments from 50 high-profile cancer papers published between 2010 and 2012. Starting in 2015, however, organizers began to pare down the number of papers due to budgetary and resource constraints. 

See “Replication Complications

“I wish we could have done more,” Tim Errington, a biologist who runs RP:CP from the Center for Open Science, tells Science. “There is an element of not truly understanding how challenging it is until you do a project like this.”

Hurdles to replicating experiments included a lack of detailed protocols and easily obtainable reagents. “Communication and sharing are low-hanging fruit that we can work on to improve,” Elizabeth Iorns, the president of Science Exchange, tells Science. 

To date, RP:CP has published 10 of the 18 replication studies in eLife. Two of the studies failed to replicate and two were inconclusive; project members were able to reproduce at least parts of the experiments from the remaining six. According to Science, the original findings from many of the 50 papers RP:CP planned to replicate have already been confirmed by other independent groups. 

RP:CP also decided to discontinue 11 ongoing replication efforts, but plans to publish the findings from those incomplete studies. 

See “Latest Reproducibility Project Study Fails to Replicate

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.